Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody

The COVID-19 pandemic has led to over 760 million cases and 6.9 million deaths worldwide. To mitigate the loss of lives, emergency use authorization was given to several anti-SARS-CoV-2 monoclonal antibody (mAb) therapies for the treatment of mild-to-moderate COVID-19 in patients with a high risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Tin, Zitzmann, Carolin, Chew, Kara W., Smith, Davey M., Daar, Eric S., Wohl, David A., Eron, Joseph J., Currier, Judith S., Hughes, Michael D., Choudhary, Manish C., Deo, Rinki, Li, Jonathan Z., Ribeiro, Ruy M., Ke, Ruian, Perelson, Alan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515893/
https://www.ncbi.nlm.nih.gov/pubmed/37745410
http://dx.doi.org/10.1101/2023.09.14.557679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515893/
https://www.ncbi.nlm.nih.gov/pubmed/37745410
http://dx.doi.org/10.1101/2023.09.14.557679

Ejemplares similares